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Despite decades of basic and clinical research, our understanding of how benzodiazepines tend to lose their eﬃcacy over time
(tolerance) is at least incomplete. In appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions
of benzodiazepines, whereas tolerance to anxiolytic and amnesic eﬀects probably does not develop at all. In light of this evidence,
we review the current evidence for the neuroadaptive mechanisms underlying benzodiazepine tolerance, including changes of (i)
the GABAA receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and
neurotrophic factors, (iii) ionotropic glutamate receptors, (iv) other neurotransmitters (serotonin, dopamine, and acetylcholine
systems), and (v) the neurosteroid system. From the large variance in the studies, it appears that either diﬀerent (simultaneous)
tolerance mechanisms occur depending on the benzodiazepine eﬀect, or that the tolerance-inducing mechanism depends on the
activated GABAA receptor subtypes. Importantly, there is no convincing evidence that tolerance occurs with α subunit subtype-
selective compounds acting at the benzodiazepine site.
1.Introduction
Shortly after their development in the 1960s, benzodi-
azepines became very popular as they exerted many desir-
able eﬀects such as reduction of anxiety, anticonvulsant
properties, and myorelaxation combined with a rather low
toxicity [1]. However, their use is associated with many side
eﬀects precluding their long-term use, including sedation,
amnesia, cognitive impairment, and ataxia. Even though
guidelines generally recommend limiting benzodiazepines to
short-term use, long-term use still often occurs. Chronic
benzodiazepine treatment can result in the development
of benzodiazepine dependence [2]. DSM-IV criteria for
benzodiazepine dependence consist of various psychological
(behavioral) and physical symptoms, including tolerance,
withdrawal symptoms when drug intake is stopped and
dose escalation [3]. Indeed, chronically treated patients
become less sensitive to some eﬀects of benzodiazepines
(tolerance) which may include anticonvulsant, sedative, hyp-
notic,andmyorelaxanteﬀectsofbenzodiazepines. Also,ben-
zodiazepine discontinuation may result in the appearance
of a characteristic withdrawal syndrome with heightened
anxiety, insomnia, and sensory disturbances [4]. In fact,
tolerance and withdrawal could be two manifestations of the
same compensatory mechanism, with withdrawal occurring
when the counterbalancing benzodiazepine eﬀect is absent
[5]. This is supported by the fact that acutely induced
benzodiazepine eﬀects are opposite to the withdrawal symp-
toms, and that changes in glucose use in the Papez circuit
(including the cingulate cortex and mammillary body) were
also observed on withdrawal, implying a common circuitry
in the withdrawal process [6]. However, physical dependence2 Advances in Pharmacological Sciences
(usually deﬁned by withdrawal symptoms) does not require
thepresenceoftolerance,andtolerancemaydevelopwithout
any signs of physical dependence [7].
Presently, despite decades of basic and clinical research,
our understanding how benzodiazepines tend to lose their
eﬃcacy over time (i.e., tolerance) is at least incomplete.
Here we review the current knowledge on the neuroadap-
tive mechanisms underlying benzodiazepine tolerance. This
paper does not speciﬁcally address the addictive properties
of benzodiazepines and their eﬀects on the dopamine system
or their abuse liability potential (including their nonmedical
use in popular culture), which are described in detail
elsewhere [8–10].
Benzodiazepine tolerance is considered to constitute an
adaptivemechanismfollowingchronictreatment,anditmay
thus be regarded as an example of neuronal plasticity. Eﬀorts
have been made to explain tolerance at the molecular or
functional level of the GABAA receptor because classical
(nonselective) benzodiazepines modulate inhibitory GABAA
receptors possessing α1, α2, α3,o rα5 subunits. On the other
hand, the excitatory glutamate system has also been impli-
catedtoplayaroleinthedevelopmentofbenzodiazepinetol-
erance [5]. Enhanced understanding of the dynamic process
leadingtoreducedbenzodiazepine eﬃcacyfollowingchronic
treatment could accelerate the development of compounds
that would maintain eﬃcacy during chronic treatment [11].
Indeed,increasingknowledgeonthespeciﬁcfunctionsofdif-
ferent GABAA receptor subunits has led to a breakthrough of
novel and more selective drugs acting at the benzodiazepine
site of the GABAA receptor. It is interesting but beyond
the scope of the review to draw a comparison between
benzodiazepine tolerance and alcohol tolerance as alcohol
(albeit with low potency) acts at the GABAA receptor [12].
Firstly, we will discuss the molecular basis of the GABAA
receptor system before taking a closer look at the clinical
aspects of the development of benzodiazepine tolerance.
Then, the putative molecular mechanisms underlying ben-
zodiazepine tolerance will be extensively discussed, followed
by a section speciﬁcally addressing the issue of tolerance
development with novel and more selective benzodiazepines
in the light of the putative tolerance mechanisms associated
with classical benzodiazepines. From a clinical perspective,
the understanding of tolerance is important because long-
term benzodiazepine treatment with continuing eﬃcacy—
using either existing or novel and more selective drugs—
could oﬀer potential beneﬁts to several groups of patients.
2.Benzodiazepinesand the GABAA System
2.1. GABAA Receptors. GABAA receptors constitute the
major fast inhibitory neurotransmitter system in the brain.
They are composed of ﬁve transmembrane-spanning sub-
units that assemble to form a ligand-gated chloride channel
with various possible subunits (α1−6, β1−3, γ1−3, δ, ε, θ,
and π) resulting in GABAA receptor heterogeneity [13].
Binding of GABA to the GABAA receptor increases the
inﬂux of negatively charged chloride ions, resulting in an
inhibitory postsynaptic signal (IPSP). Although in theory a




















Figure 1: Representation of the GABAA receptor structure. The
inhibitory GABAA receptor consists of ﬁve subunits that together
form a ligand-gated chloride (Cl −) channel (a). When GABA binds
(between the α and the β subunit of the GABAA receptor), chloride
ionsﬂowintotheneuron,resultinginahyperpolarizationofthecell
membrane (a). Classical nonselective benzodiazepines allosterically
enhance the inhibitory actions of GABA by binding between the α1,
α2, α3,o rα5 subunit and the γ subunit (b). Although the GABAA
receptor displays a large molecular heterogeneity depending on the
subunitcomposition,themostcommonsubtypeisapentamerwith
2α,2 β, and 1γ subunit.
GABAA receptors are found in typical subunit compositions
with the most common receptor subtype being composed
of two α,t w oβ,a n do n eγ subunit [14]( Figure 1). In
situ hybridization and immunohistochemical studies have
shown that GABAA receptor subunits display a distinct
CNS distribution with a diﬀerential cellular localization
pattern, suggesting that GABAA receptor subunits have a
specializedfunction(Table 1)[14].Overall,ahighexpression
of GABAergic subunits is present in the cortex, hippocam-
pus, and basal ganglia [15]. Of the GABAergic subunits,
α1, β1, β2, β3,a n dγ2 subunits are found throughout
the brain. In contrast, the α2, α3, α4, α5, α6, γ1,a n dδ
subunits have a speciﬁc regional expression pattern. The
α1 subunit is highly coassembled with β2 and γ2 subunits
and is synaptically located on neuronal cell bodies. GABAA
receptors that contain an α2 or α3 subunit are less abundant
and are codistributed with the β3 and γ2 subunits. The α2
subunit is present in the cortex, hippocampus, amygdale,
and hypothalamus, and often its expression is negatively
correlated with the expression of α1 subunits. The expression
of the α3 subunit is highest in the cortex, hippocampus,Advances in Pharmacological Sciences 3
Table 1: Localization of common GABAA receptor subtypes in the

















Cerebral cortex (layers V-VI),
hippocampus, cerebellum,
amygdala, brainstem (including

















amygdala, thalamus, and brainstem, although it is also
expressed in monoaminergic neurons (e.g., the raphe nuclei
and the locus coeruleus in the brainstem) and cholinergic
neurons in the forebrain. α5 subunits are predominantly
expressed in the hippocampus where they comprise 15–20%
of the diazepam-sensitive GABAA receptors [16]. Regarding
cellular localization, cortical and hippocampal pyramidal
cells receive input from morphologically distinct GABAergic
interneurons that innervate diﬀerent pyramidal cell parts
depending on the type of interneuron (e.g., chandelier and
basket cells) with a specialized postsynaptic expression of α
subunits [17, 18].
Thus,GABAA receptorsubtypesprobablypossessdiverg-
ing functional properties dependent on the subunit compo-
sition, contributing to the GABA signaling complexity [13].
Additionally, GABAA receptors are found synaptically as well
as extrasynaptically. Synaptic receptors usually contain γ
subunits and mediate fast phasic inhibition accompanied
by transient high GABA concentrations [16]. By contrast,
GABA has higher potency (at μM concentrations) at
extrasynaptic GABAA receptors that usually contain a δ
subunit, preferentially assemble with α6 or α4subunits and
have slow desensitization kinetics [20]. Also, α5 subunits
may be localized extrasynaptically [21]. Extrasynaptic tonic
inhibition—which is not modiﬁed by benzodiazepines—
is suggested to modulate excitability of neuronal networks
throughout the brain.
2.2. Benzodiazepines from a Nonspeciﬁc towards a Subunit-
Speciﬁc Pharmacology. Classical benzodiazepines allosteri-
cally modulate GABA-induced IPSPs by binding to the
benzodiazepine site of GABAA receptors that contain an α1,
α2, α3,o rα5 subunit in combination with a β and a γ2
subunit(Figure 1).Theexactbindingsiteofbenzodiazepines
at the GABAA receptor is located between the α and γ
subunit. In contrast, benzodiazepines do not interact with
GABAA receptors that contain an α4-o rα6-subunit. In
addition to benzodiazepines, other drug classes can bind
to the GABAA receptor complex, including several anti-
convulsants, ethanol, barbiturates, neurosteroids, and some
anesthetics [15]. The fact that classical benzodiazepines non-
selectively bind to diﬀerent α subunits led to the hypothesis
that the pharmacological proﬁle with anxiolytic, sedative,
anticonvulsive and myorelaxant properties may be further
dissected. Both genetic and pharmacological approaches
explored the hypothesis that α subunits diﬀerentially con-
tribute to the diﬀerent eﬀects of classical benzodiazepines
The genetic approach consisted of point mutations into
speciﬁc α subunits (α1(H101R), α2(H101R), α3(H126R),
and α5(H105R)), turning them functionally insensitive to
benzodiazepines without altering their GABA sensitivity
[22]. Pharmacological research on the GABAA receptor
has focused on the development of compounds that show
diﬀerential eﬃcacy across the various α subunits [13]. Such
drugs generally bind with equal aﬃnity to all α subunits (i.e.,
α1, α2, α3,a n dα5 subunits), but selectively alter the capacity
to increase GABA binding to one or more of them. Using
t h i ss t r a t e g y ,v a r i o u se ﬃcacy-selective (and some aﬃnity-
selective) compounds have been developed with preferential
agonistic activity at the α1 (zolpidem and zaleplon), α2/3
(TPA023, L838, 417, and SL651498), or inverse agonistic
activity the α5 subunit (α5IA, L-655,708, and MRK-016) (see
also Table 2).
In line with a speciﬁc central localization and distribu-
tion of GABAergic subunits, these genetic and pharmacolog-
ical approaches have demonstrated that diﬀerent α subunits
of the GABAA receptor mediate the distinct eﬀects of
benzodiazepines. Speciﬁcally, α1-containing GABAA recep-
tors probably mediate the sedative, amnesic, and anti-
convulsant actions of classical benzodiazepines [13, 23].
In contrast, muscle relaxation and anxiety reduction after
benzodiazepine administration was primarily ascribed to
α2 (and possibly α3) subunit activation [24], whereas α5
subunit-containing GABAA r e c e p t o r sa p p e a rt ob ei n v o l v e d
in learning and memory [25, 26].
In light of the topic of this review, studies investigating
the contribution of GABAergic subunits in benzodiazepine
abuse liability, drug reinforcement, and tolerance devel-
opment are of particular interest. Unfortunately, studies
applying genetic and subtype-selective methodologies to
examine the development of tolerance are scarce. One
study using α subunit point mutation mice implicated a
critical role for α5 subunits together with α1 subunits in the
decreasing sedative eﬃcacy of the classical benzodiazepine
diazepam after chronic treatment [27]. We will discuss
this ﬁnding in detail later in this paper. Studies on the
background of physical dependence and abuse liability using
subtype-selective GABAAR modulators are more abundant.
Using self-administration studies, it was shown that eﬃcacy
at α1-containing GABAA subtypes signiﬁcantly contributed
to the reinforcing eﬀects and withdrawal symptoms of
benzodiazepines [8, 28, 29]. Speciﬁcally, TPA123, which
still possesses 23% intrinsic activity at α1 subunits still led4 Advances in Pharmacological Sciences
Table 2: Summary of novel GABAA receptor subtype selective compounds.
Target Name Eﬃcacy
(compared to a classical benzodiazepine) Aﬃnity/Remarks Ref
α1 Zolpidem Comparable at α1/α2/α3/α5
5-10-fold higher aﬃnity for α1 versus
α2/3 > 1000 fold higher aﬃnity for α1
versus α5
[15]
α2/3 TPA023 α1 (0%), α2 (11%), α3 (21%), α5 (5%) Equivalent aﬃnity [8]
α2/3 TPA123 α1 (23%), α2 (35%), α3 (43%), α5 (19%)
Equivalent aﬃnity. Reinforcing eﬃcacy
and physiological dependence remained
present
[8]
α2/3 L838,417 α1 (1.5%), α2 (43%), α3 (43%), α5 (39%) Equivalent aﬃnity [23]
α2/3 SL651498 α1 (45%), α2 (115%), α3 (83%), α5 (50%)
Compared to zolpidem for α1 eﬃcacy
5–10-fold increased aﬃnity for α2/3, 10–20
fold lower aﬃnity for α5
[31]
to benzodiazepine-like drug reinforcement and withdrawal
symptoms, whereas TPA023 with 0% α1 intrinsic activity
did not, even at full GABAA receptor-binding capacity [8].
However, there is still the possibility that the lower α2 and α3
eﬃcacy of TPA023 may have contributed to the absence of
drug reinforcement and withdrawal. In support, L-838,417
also led to continued self-administration, even though it
lacks eﬃcacy for the α1 subtype [30]. In any case, the α5
subunit may not be directly involved in the abuse potential
of classical benzodiazepines as the α1-preferring hypnotic
zolpidem with no aﬃnity for the α5 subunit still led to self-
administration in primates [30]. This ﬁnding is surprising as
it suggests that the α5 subunit may be involved in tolerance
development but not in drug reinforcement. Consequently,
these processes could be independently mediated, even
though they are both incorporated in the deﬁnition of
benzodiazepine dependence.
2.3. GABA Metabolism. As benzodiazepines enhance the
inhibitory eﬀects of GABA and shift the GABA concentra-
tion-response curve to the left, the synaptic GABA concen-
tration aﬀects benzodiazepine eﬃcacy. GABA is converted
from glutamate by the enzyme glutamic acid decarboxylase
(GAD) that maintains intracellular levels of GABA and
exists in two independent isoforms (GAD65 and GAD67). In
contrast to the localization of GAD67 in the neuronal body,
GAD65 is primarily expressed in axon terminals, suggesting
ar o l ef o rG A D 65 in synaptic neurotransmission and a
more general role for GAD67 in regulating GABA synthesis
[32]. Synaptic GABA is removed from the cleft into the
presynapticaxonterminalsbyGABAtransporters(GATs).So
far, four GAT subtypes have been identiﬁed, with the highly
expressed GAT1 and GAT4 being the most widely distributed
[33].
3. The Development of
BenzodiazepineTolerance
Before examining the possible mechanisms underlying the
development of benzodiazepine tolerance after long-term
exposure, it is important to review its evidence and deter-
mine whether it is clinically relevant. Overall, there is
little doubt that benzodiazepines are acutely eﬀective in
reducing anxiety, sleep latency and preventing convulsions.
The tolerance that is eventually thought to develop appears
to occur at diﬀerent rates and to a diﬀerent degree for
each of the benzodiazepine eﬀects [34]. Preclinical studies
have shown that tolerance to the sedative and hypnotic
eﬀects occurs rather rapidly, followed by tolerance to the
anticonvulsant eﬀects, whereas tolerance to the anxiolytic
eﬀects of benzodiazepines are absent or partially develop
after long-term treatment (for reviews, see [34–36]).Asthese
preclinical studies have already been extensively reviewed,
and novel preclinical studies on benzodiazepine tolerance
have been limited in the last years to our knowledge, it
is beyond this paper to reproduce all preclinical data on
tolerance development. In general, preclinical studies are in
agreement with the clinical divergent picture, even though in
most preclinical studies, tolerance is not directly related to
the applied dose, dosing interval, or the drug’s plasma levels
or half-life. Here, we will focus on the clinical evidence for
(the rate of) tolerance development for each benzodiazepine
action, even though we will also include preclinical studies
when clinical studies are lacking or inconclusive.
3.1. Clinical Studies on Sedative and Hypnotic Tolerance.
A study in low-dose benzodiazepine-dependent subjects
showed a complete loss of hypnotic activity independent of
the half-life of the prescribed benzodiazepine, even though
a substantial suppression of REM sleep still occurred [37].
Also, other studies have shown that chronic users displayed
no increase in sedation or motor impairment after the acute
application of a benzodiazepine [38–40]. Moreover, toler-
ance to benzodiazepine-induced decreased reaction speed
was shown after 10 days of alprazolam treatment [41]. Oral
administration of triazolam, a short acting benzodiazepine,
initially improved both sleep induction and maintenance,
but latency to sleep and the number of awakenings were
back to baseline values after two weeks of triazolam use [42].
Importantly, early-morning insomnia associated with short-
acting benzodiazepines triazolam and midazolam markedly
worsenedafter7daysoftreatment[43].However,conﬂicting
studies with triazolam exist that did not show any tolerance
development [44, 45]. Another study applying the longer-
actingbenzodiazepinetemazepam(15or30mg)foreither26Advances in Pharmacological Sciences 5
or 54 nights in 7-8 subjects with chronic insomnia found no
development of drug tolerance due to long-term temazepam
administration [46]. Flurazepam, which has a relatively long
elimination half-life, was shown to be eﬀective for initiating
and maintaining sleep with intermediate and long-term use
(over 4 weeks), even though daytime sedation diminished
during prolonged use [47]. Thus, even though tolerance to
the sedative eﬀects quickly emerges in most studies, these
eﬀects seem to be most prominent with benzodiazepines
with a short half-life. Tolerance could thus depend on
the half life of the applied benzodiazepine. However, this
may be an overgeneralization, as a review showed that
tolerance in human subjects only marginally emerged after
chronic treatment with the short-acting drugs midazolam
and zolpidem, even though the short-acting drug triazolam
was associated with tolerance [48]. A limitation of most
studies is their relatively short duration of exposure. Another
issue is that convincing evidence for improved sleep after
long-term use is lacking [49], yet this may not be the
sole result of tolerance but could also be attributable to a
g e n e r a l i z e dl a c ko fe ﬃcacy. In support, in human subjects,
discontinuation of benzodiazepines did not decrease sleep
quality compared to a group that stayed on benzodiazepines
up to 52 weeks after cessation [50], or even increased
sleep quality and slow wave sleep after discontinuation in
insomnia patients [51].
3.2. Clinical Studies on Anticonvulsant Tolerance. The use of
benzodiazepines over a longer period of time in epilepsy is
limitedduetothedevelopmentoftolerance[52].Inlinewith
preclinical studies [53–55], tolerance develops during the
ﬁrst several months in 30–50% of epilepsy patients treated
with either clobazam or clonazepam [56]. Thus, benzodi-
azepines are only prescribed in acute epileptic seizures or in
a status epilepticus. However, in certain cases, intermittent
use may be indicated, which may reduce the likelihood
of tolerance [57]. Chronic treatment in rodents with the
α1-preferential compound CL218, 572 resulted in loss of
picrotoxin-induced seizures [58]. In contrast to classical
benzodiazepines, partial GABAA receptor PAMs including
bretazenil did not result in anticonvulsant tolerance in
several preclinical studies [54, 59, 60]. However, to our
knowledge, these drugs have not been tested for (contin-
uing) anticonvulsant activity in humans, precluding ﬁrm
conclusions on their tolerance-inducing eﬀects in epilepsy
patients.
3.3. Clinical Studies on Amnesic Tolerance. Most studies have
foundcontinuedshort-termmemoryimpairmentafteracute
administration of benzodiazepines in chronically treated
subjects [38, 39, 61]. Also, no tolerance for memory-
impairing eﬀects of alprazolam was found during a 10-day
acute treatment [41]. However, another study reported toler-
ance to the acute amnesic eﬀects of alprazolam after chronic
use [40]. A major concern is that loss of memory associated
with benzodiazepine use may be lasting, even after treatment
discontinuation [62, 63], although other studies reported
improved cognitive functioning after discontinuation with
increased speed and accuracy of information processing,
improved reaction time and working memory [50, 64–66].
Collectively, clinical data do not support the existence of
tolerancetobenzodiazepine-induced cognitive impairments.
3.4. Clinical Studies on Anxiolytic Tolerance. If developing
al all, tolerance to the anxiolytic eﬀects seems to develop
moreslowlycomparedtotolerancetothehypnoticeﬀects.In
patients with panic disorder, neither anxiolytic tolerance nor
daily dose increase was observed after 8 weeks of alprazolam
treatment with continued eﬃcacy [67]. This was conﬁrmed
by another study in panic disorder patients who already
chronicallytookalprazolam.Here,nodiﬀerenceswerefound
in cortisol responsivity or anxiolytic eﬃcacy compared to
alprazolam-na¨ ıve patients, independent of disease severity
[40]. Another double-blind study allocated 180 chronically
anxious outpatients to diazepam (15 to 40mg/day) and
found that prolonged diazepam treatment (6–22 weeks)
did not result in tolerance to the anxiolytic eﬀects of
diazepam [68]. Furthermore, additional studies all show a
continuing anxiolytic eﬀect, at least for panic disorder [69–
72],generalizedanxietydisorder[73],andsocialphobia[74–
76]. Although a declining anxiolytic eﬃcacy after long-term
use of benzodiazepines cannot be clearly established, it is
important to remember that other disadvantages prevent
benzodiazepines to chronically treat anxiety symptoms,
such as continued memory impairment, accident risk, hip
fractures, and withdrawal symptoms [7, 77]. In conclusion,
there is no solid evidence from the existing literature that
anxiolyticeﬃcacydeclinesfollowingchronicbenzodiazepine
use in humans.
3.5. Clinical Studies on Drug Reinforcement Tolerance. The
relevant topic of benzodiazepine tolerance to the reinforcing
eﬀects of benzodiazepines was already discussed by Licata
and Rowlett [9]. They concluded that tolerance to reinforc-
ing eﬀects of benzodiazepines appears unlikely, supported
by studies in nonhuman primates in which midazolam
and zolpidem maintained stable self-injection and phys-
ical dependence under conditions of chronic continuous
availability [78, 79]. Also, in humans, tolerance to drug
reinforcement could lead to dose escalation that would
maintain the vicious cycle of tolerance and dependence. In
clinical practice, the majority of patients do not escalate their
dose, suggesting that drug reinforcement tolerance may not
emerge [80].
3.6. Conclusion. In conclusion, tolerance develops relatively
quicklyforthesedative,hypnotic,andanticonvulsantactions
of benzodiazepines. Tolerance to anxiolytic and amnesic
eﬀects most probably does not appear at all. The fact that
benzodiazepine dosage may be hard to reduce after chronic
use can be ascribed to physical dependence to avoid with-
drawal symptoms rather than the development of tolerance.
With diverging rates and varying completeness of tol-
erance development, it may be speculated that either (i)
diﬀerent tolerance mechanisms exist depending on the
benzodiazepine eﬀect, or that (ii) a uniform mechanism
accounts for tolerance but revolves around the subunit
composition of the targeted GABAA receptor subtype and6 Advances in Pharmacological Sciences
the brain region involved. However, from the presented
evidence it is diﬃcult to conclude that benzodiazepines
indeed produce a robust and reproducible tolerance for
all (side) eﬀects. It is clear however, that benzodiazepine
tolerance is not a uniform process for all clinical eﬀects and
does not apply to all available benzodiazepines. However,
it is not known which factors predict whether a certain
benzodiazepine possesses the potential to produce tolerance.
Unfortunately,manystudiesaddressthephysicaldependence
of benzodiazepines and their abuse potential, but do not
speciﬁcally investigate tolerance.
4. Mechanisms UnderlyingTolerance
4.1. General. Decades of research into the molecular eﬀects
of long-term benzodiazepine treatment have already impor-
tantly advanced our understanding of tolerance and several
excellent reviews on this topic have already been published
[5, 11, 34, 77]. The general assumption is that chronic
benzodiazepine use leads to compensating changes in the
central nervous system. This way, the GABAA receptor
may become less responsive to the continuing acute eﬀects
of benzodiazepines, either as a result of adaptations in
the GABAA receptor itself, intracellular mechanisms, or
changes in other neurotransmitter systems, such as the
glutamatergic system. Although adaptive processes probably
play an important role, it is important to realize that
the development of tolerance is not uniform for all its
actions, and diﬀerences between preclinical and clinical
tolerance development may exist. Therefore, the possibility
that not one but multiple adaptive mechanisms simulta-
neously coexist complicates research into benzodiazepine
tolerance. Moreover, these adaptive changes could be limited
t oo n eo rm o r es p e c i ﬁ cb r a i na r e a s .T h i sm a k e si tv e r y
challenging to single out one a priori unifying mechanism
underlying tolerance. In support, a study in rats using
2-deoxyglucose quantitative autoradiography showed that
duringchronicdiazepamtreatment,heterogeneoustolerance
to the diazepam-induced reduction of glucose utilization
occurred in the brain, depending on treatment duration and
brain region [6]. Whereas acute diazepam administration
resulted in reductions in glucose utilization throughout the
brain, 3 days of diazepam treatment led to tolerance in
brain structures associated with sensory processing (pari-
etal cortex, auditory cortex, cochlear nucleus) which was
interpreted to correlate with reduced sedation. After 28-
day diazepam treatment, tolerance to the depressant eﬀect
of diazepam on cerebral glucose occurred in the mamillary
body, subiculum, and caudate nucleus, whereas changes in
the frontal cortex approached signiﬁcance. Of particular
interest is the ﬁnding that none of the amygdaloid nuclei
showed any blunting over time, in line with persistent
anxiolytic eﬀects of benzodiazepines.
Before taking a closer look at speciﬁc mechanisms that
have been proposed to underlie benzodiazepine tolerance, it
is important to note that pharmacokinetic factors probably
do not play a major role in the development of tolerance
[81].Insupport,plasmalevelsafteracutediazepamadminis-
trationdidnotdiﬀerbetweenchronicallyalprazolam-treated
and untreated panic disorder patients, even though sedative
and amnesic tolerance was observed [40]. The most obvious
candidate to mediate the adaptive changes in cellular and
synaptic function after chronic benzodiazepine treatment
is the GABAA receptor. Therefore, we will ﬁrst discuss the
evidence supporting changes in the GABA system (including
GABAA receptor coupling and GABA receptor expression)
after chronic benzodiazepine exposure.
4.2. GABAA System Hypotheses
4.2.1. Mechanism 1: GABAA Receptor Uncoupling. One ex-
planation for a loss of benzodiazepine function is a loss in
GABAA receptor allosteric coupling. The GABAA receptor
contains two GABA-binding sites and one benzodiazepine-
binding site that are allosterically coupled, that is, binding
to the benzodiazepine-binding site potentiates binding of
GABA to the GABA-binding site (Figure 1). Benzodiazepines
are generally referred to as positive allosteric modulators
(PAMs) because their binding alters the GABAA receptor
conformation with an increased capacity to bind GABA,
leading to increased channel opening frequency, increased
chloride inﬂux, and, consequently, to hyperpolarization.
GABAA receptor uncoupling is deﬁned as a decreased ability
of benzodiazepines to enhance GABA-induced IPSPs at the
GABAA receptor. In terms of tolerance development, it has
been hypothesized that chronic treatment aﬀects the benzo-
diazepines’capacitytopharmacologicallyenhancetheGABA
response (i.e., tolerance leads to uncoupling). A decreased
coupling may develop as a result of changed GABAA receptor
subunit composition, alterations to the GABAA receptor
itself (including phosphorylation) or its second messenger
ligands, or any process aﬀecting the conformational state of
the GABAA receptor. The receptor uncoupling hypothesis
is attractive as it does not assume any changes in subunit
expression and ligand binding yet uses the knowledge on
the specialized functions of the GABAA receptor and the
diﬀerent subunits. However, the uncoupling process is an
aspeciﬁc process as it can be induced by exposure to diﬀerent
classes of GABAA receptor modulators acting at diﬀerent
modulatory sites, such as neurosteroids and barbiturates
[82].
Already in 1984, an electrophysiological study indicated
that allosteric coupling may play a role by showing a 50%
decrease in the GABA enhancement of benzodiazepine-
binding without signiﬁcant changes in benzodiazepine-
binding site density or aﬃnity [83]. Also, more recent
indications for reduced allosteric coupling were found after
chronic treatment using transfected cell lines that express
GABAA receptors or in neurons [84–94]. The mechanisms
underlying possible diﬀerences in coupling remain poorly
understood. If the GABAA receptor assembly process is
modiﬁed, GABA receptor composition can be modiﬁed
due to subunit replacements or altered expression in the
receptor. This way, GABAA r e c e p t o r sw i t had i ﬀerent func-
tionality could potentially possess reduced benzodiazepine
sensitivity due to reduced GABAA receptor coupling. To
our knowledge, no studies exist which have directly inves-
tigated GABAA receptor subunit composition after chronicAdvances in Pharmacological Sciences 7
exposure. Another mechanism to aﬀect receptor coupling
is GABAA receptor phosphorylation. GABAA receptors are
phosphorylated by various protein kinases and dephospho-
rylatedbyphosphatases[95].Dynamicfunctionalalterations
in GABAA receptor phosphorylation status may directly
aﬀect the inhibitory synaptic strength, with changes in
channel openings (or indirectly inﬂuence receptor traf-
ﬁcking). However, the precise eﬀects of phosphorylation
on neuronal GABAA receptor function are complex, even
though key residues within the intracellular loop of the
GABAA receptor seem of particular importance. Using
whole-cellpatch-clamprecordingsof GABAA receptorIPSCs
in hippocampal neurons, brain-region-dependent eﬀects
of activation of cAMP-dependent protein kinase A (PKA)
or Ca2+/phospholipid-dependent protein kinase C (PKC)
were shown [96]. Also, PKA activity was found to be
directly involved in changed GABAA receptor functioning in
hippocampal pyramidal cells following chronic ﬂurazepam
treatment [97]. Probably, phosphorylation patterns rather
than individual sites are of importance, supported by the
ﬁnding that mutation to one PKA phosphorylation site is
not involved in tolerance [90]. Using a point mutation
genetic approach, transcriptional reduction was found in
calcium-/calmodulin-dependent kinase IIα and MAP kinase
phosphatase-1in control mice but not in α1(H101R) after
acute administration of diazepam [98]. Unfortunately, no
chronic treatment was included in these studies.
It remains to be seen whether changes in allosteric
coupling arerelevantto the development oftolerance invivo.
Because benzodiazepine tolerance gradually develops over
days to weeks, this would suggest that structural changes
take place, whereas posttranslational compensation would
be expected to be directly manifest. In support, uncoupling
seems to develop rapidly, with the classical benzodiazepine
chlordiazepoxide (applied together with GABA) stimulating
the rate and extent of desensitization produced in a single
neuron within several seconds [99]. Also, the observed
uncouplingafterchronicbenzodiazepinetreatmentisrapidly
reversed by a brief exposure in vivo to the benzodiazepine
antagonist ﬂumazenil [83, 86].
4.2.2. Mechanism 2: Alterations in GABAA Receptor Subunit
Expression. The most straightforward hypothesis to explain
impaired sensitivity after chronic benzodiazepine exposure
would be a general downregulation of GABAA receptors
throughout the brain. Indeed, the process of tolerance
requires GABAA r e c e p t o r sa tl e a s tt os o m ee x t e n t ,a sc e lll i n e s
expressing one speciﬁc type of the GABAAR are susceptible
to tolerance [86, 87, 90]. Because classical (nonselective)
benzodiazepines bind to GABAA receptors that contain an
α1, α2, α3,o rα5 subunit, it could be expected that expression
of receptors containing these α subunits (plus a γ2 subunit)
is changed. Of course, this would depend on the cellular and
anatomical distribution of GABAA receptors. Already earlier
in Section 2.1, the diﬀerentiated and unique distribution of
GABAergic subunits in the CNS was discussed. With regard
to the benzodiazepine-sensitive α subunits, the α1 subunit
is ubiquitously expressed in the entire brain, whereas the
other α subunits (α2, α3 and α5) display a more restricted
patternofexpression(seeTable 1).Ifreceptorinternalization
simply downregulates GABAA receptor density, then a priori
regional diﬀerentiation would be expected based on receptor
distribution.
The processes that control the assembly, membrane traf-
ﬁcking, and synaptic accumulation of GABAA receptors are
complex (for review, see [100]). In short, GABAA receptors
are assembled from individual subunits out of the endo-
plasmic reticulum within minutes after their translation,
with amino acid sequences in the N-terminus inﬂuencing
the GABAA receptor subtype (Figure 2). Then, receptor
traﬃckingtotheplasmamembranetakesplace,facilitatedby
diverse helper GABAA receptor-associated proteins (among
that GABARAP, BIG2, PRIP, gephyrin, and radixin). Ulti-
mately, (clathrin-dependent) endocytosis occurs after recep-
tor dephosphorylation, after which degradation or recycling
may ensue (Figure 2) .I fp r o l o n g e da c t i v a t i o no ft h eG A B A
system leads to receptor downregulation, then this could be
established by interfering at multiple steps of the dynamic
GABAA receptor life cycle. These include decreased subunit
mRNA transcription, subunit degradation in the endoplas-
mic reticulum (e.g., by ubiquitylation), decreased expression
of GABAA receptor-associated helper proteins, and alter-
ations in the endocytosis of speciﬁc GABAA receptor sub-
types. The ﬁnding that the protein synthesis inhibitor cyclo-
heximide and the RNA synthesis inhibitor actinomycin D
blockedtheeﬀectsofchronicdiazepamexposureinrecombi-
nant cells expressing GABAA receptors indicates that GABAA
receptor synthesis is of at least some importance [87].
Up to now, a plethora of studies have tried to address
whether chronic benzodiazepine treatment indeed aﬀects
GABAA receptor expression (and thus benzodiazepine bind-
ing sites) using compounds with diﬀerent subtype selectivity
p r o ﬁ l e sa td i ﬀerent doses and varying treatment duration. A
recentexcellentreviewsummarizedalldataontheregulation
of GABAA receptor subunit after chronic benzodiazepine
treatment that was mostly studied in rats [102]. It is beyond
the scope of this review to repeat the meticulous work
laid down in this paper. Of all subunits, α, β,a n dγ
subunits have been mostly examined. This paper conﬁrms
that both for mRNA and protein subunit levels, the available
evidence leads to a divergent and sometimes conﬂicting
picture, although the majority of the studies essentially do
not show any signiﬁcant diﬀerence in subunit expression
[102].Furthermore,alackofconsistencyappearsforsubunit
changes in diﬀerentspeciﬁcbrainareas.Moreover,thelength
and method of chronic treatment seem relevant since diﬀer-
ences in GABAA receptor subunit mRNA levels after chronic
diazepamtreatmentinratscandependonwhetherdiazepam
is administered as daily systemic injections or via osmotic
minipumps [103]. Binding studies also generally report no
changes in benzodiazepine binding after chronic treatment
[92, 93, 104]. Together, GABAA receptor expression (both
mRNA and protein levels) is not consistently and robustly
altered after various long-term treatment regimens. Thus, a
general central downregulation or even consistent region-
speciﬁc changes in GABAA receptor expression after chronic
benzodiazepine use are not supported by the literature. Even
































Figure 2: GABAA receptor traﬃcking and associated proteins. GABAA receptors are assembled from individual subunits in the
endoplasmatic reticulum (ER) where the chaperones BiP and Calnexin assist in quality control. Unassembled GABAA receptor subunits
that are to be targeted for ER-associated degradation are ubiquitinated and degraded in the proteasome. The ubiquitin-like protein PLIC can
interact with GABAA receptors thereby inhibiting their targeting for proteasomal degradation. Assembled pentameric GABAA receptors exit
theERandbindtheguanidineexchangefactorbrefeldin-A-inhibitedGDP/GTPexchangefactor2(BIG2)intheGolgi.Heretheyalsointeract
withthepalmitoylasetransferaseGODZandGamma-aminobutyricacidreceptor-associatedprotein(GABARAP).GABARAPinteractswith
the NEM sensitive fusion (NSF) protein, as does the GABAA receptor β subunit, and this association may facilitate transport of the receptor
complexes to the cell surface. GABAA receptors are inserted at extrasynaptic sites and can diﬀuse along the plasma membrane in and out
of synaptic domains. At synapses they are stabilized by an interaction with the scaﬀolding protein Gephyrin. The interaction of the GABAA
receptor intracellular loops with the μ2 subunit of the adaptin complex AP2 is important for GABAA receptor internalization. GABAA
receptors are delivered by a clathrin-mediated pathway to early endosomes where they can be targeted for degradation in the lysosome or
for recycling upon binding of Huntington-associated protein (HAP1). Reprinted by permission from Elsevier, reprinted from [101].Advances in Pharmacological Sciences 9
species, route of administration, and applied drug) may
account for some conﬂicting ﬁndings, the results seem over-
all inconsistent. Moreover, molecular results are often not
combined with behavioral tests, preventing a direct corre-
lation between behavioral tolerance and molecular changes.
Clinical studies applying in vivo binding or postmortem
GABAA receptor expression after chronic benzodiazepine
treatment are to the knowledge of the authors lacking.
Changes in rates of GABAA receptor endocytosis, recep-
tor membrane insertion, intracellular traﬃcking, and asso-
ciation with helper GABAA receptor-associated proteins
could still play a role, leading to a reduction in membrane
surface receptors without aﬀecting overall subunit protein
expression (e.g., see [105]). Another interesting suggestion
is that a possible loss of synaptic function after chronic
exposure could be due to a shift to a perisynaptic or even
an extrasynaptic localization of GABAA receptors, away
from clustering of GABAA r e c e p t o r sa ts y n a p s e s( Figure 2)
[106]. At least in alcohol research, such dynamic changes
in plasticity at inhibitory synapses have been shown [107].
Moreover, it cannot be excluded that particular subunits
play a role in the development of tolerance after chronic
treatment in the absence a direct up- or downregulation.
Using the previously mentioned α subunit point mutation
mice, acutely administered diazepam still reduced locomotor
activity in α5 (H105R) mice even after chronic 8-day
diazepam treatment at a combined daily dose of 15mg/kg
[27].Thissuggeststhattheα1 subunitthatmediatestheseda-
tive eﬀects remains responsive, indicating that simultaneous
activation of the α1 and α5 subunit may be necessary for
tolerance to the locomotor-reducing eﬀects of classical ben-
zodiazepines. Speciﬁcally, it was hypothesized that increased
phasic signaling would alter extrasynaptic tonic inhibition
mediated by α5-containing GABAA receptors, whereas a
decrease in hippocampal α5-speciﬁc binding was reported
in diazepam-tolerant mice. Also, in contrast to α1-, α2-, and
α3-containing receptors, α5-containing GABAA receptors are
locatedextrasynapticallyatthebaseofdendriticspineswhere
they can modulate excitatory glutamatergic input. However,
α1(H101R) mice are not sensitive to the acute sedative
benzodiazepine eﬀects, making a comparison to isolated α1
subunit activation not possible. Moreover, only tolerance to
the sedative eﬀects of diazepam was reported. Thus, it may
stillbe possible thattolerancetootherbenzodiazepine eﬀects
is mediated by other subunits.
4.3. Glutamate System Hypotheses
4.3.1. General. From the previous sections, we conclude
that compensatory changes solely arising from the GABA
system may at most partially explain the tolerance arising
following chronic treatment with benzodiazepines. Gluta-
mate is an excitatory neurotransmitter acting on glutamate
receptors. Together with the GABA system, they constitute
the two fast-acting and opposing neurotransmitter systems
that can modulate synaptic plasticity. In support, close
neuroanatomical connections exist between GABAergic and
glutamatergic neurons [108, 109]. With a presence in at
least 30–50% of all synapses in the CNS, inhibitory GABA
and excitatory glutamate together coordinate the balance in
the brain’s excitability. Therefore, it is not surprising that as
these two opposing and fast-acting neurotransmitter systems
form a delicate balance, chronic (increased) activation of
theGABAergicsystemduringbenzodiazepinetreatmentmay
pertubate glutamatergic transmission. The basis of benzo-
diazepine tolerance could then lie in sensitization of the
glutamatergic system—a putative process that could account
for the withdrawal symptoms after chronic benzodiazepine
discontinuation [5, 110]. Such sensitization is reminiscent to
adaptive glutamatergic processes as seen in kindling experi-
ments, although it should be noted that kindling only occurs
with intermittent and not after continuous treatment [111].
Glutamatergic sensitization could thus play a role in the
development of tolerance as well as withdrawal symptoms
upon cessation of treatment. Glutamatergic changes after
benzodiazepine withdrawal will not be discussed here, but
there are indications that the glutamatergic system plays a
role in withdrawal states with accompanying increases in
anxiety and seizure activity (for review see [5]). However,
glutamate receptor mRNA and protein changes may be
dynamic during withdrawal, with unchanged levels during
the early phase of withdrawal but changes occurring several
days later [112]. This consequently complicates the interpre-
tation of withdrawal studies and their signiﬁcance for our
understanding of benzodiazepine tolerance.
Similar to the GABAergic system, the glutamate sys-
tem is diverse and complex, generally being divided into
ionotropic and metabotropic receptor types. Ionotropic
glutamate receptors form a class of heteromeric ligand-gated
cation channels that potentiate the inﬂux of K+,N a +,o r
Ca2+ ions following glutamate binding. Three classes of
the ionotropic glutamate receptor occur in het central ner-
vous system: the NMDA receptor (N-methyl-D-aspartate),
the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4-
isoxazole-4-propionic acid), and the kainate receptor (for
a recent review see [113]). Functional NMDA receptors
contain two obligatory GluN1 and two regulatory GluN2/3
subunits and are vital for synaptic plasticity (for review,
see [114]). Each GluN subunit contains extracellular loops
where coagonists glycine or D-serine (GluN1 and GluN3
subunits) and glutamate (GluN2 subunits) can bind [115].
Although the channel is blocked by Mg2+ ions, changes
in membrane potential can make the channel permeable
to Na+,C a 2+,a n dK + ions. The central distribution of
GluN2 subunits eventually ensures heterogeneity in the
NMDA receptor system. AMPA receptors are widespread
heterotetrameric ligand-gated ion channels composed of
fourtypesofsubunits(GluR1–4),andarecrucialtolong-term
synaptic plasticity suchas long-term potentiation (forreview
see [116]). Although glutamate possesses lower aﬃnity
for the AMPA receptor compared to NMDA receptors,
faster excitation-inducing kinetics are present at the AMPA
receptor. Relevant to this review, a study showed that AMPA
receptor desensitization was caused by a rupture of a domain
interface which allowed the ion channel to close, providing
a simple yet elegant explanation [117]. Kainate receptors
are made up of four subunits, GluR5,G l u R 6,G l u R 7,K A 1,
and KA2, which are similar to AMPA and NMDA receptor10 Advances in Pharmacological Sciences
subunits and can be arranged in diﬀerent ways to form
a functional tetramer (for review, see [118]). Compared
to NMDA and AMPA receptors, synaptic kainate receptors
exhibit slow rise and decay properties.
4.3.2. Mechanism 3: Role of Ionotropic Glutamatergic Recep-
tors. Several studies have addressed the compensatory gluta-
matesensitizationhypothesisduringchronicbenzodiazepine
exposure to account for the development of tolerance (as
reviewed by [5, 110]).
In rodents, the development of tolerance to the seda-
tive eﬀects of the classical benzodiazepines diazepam and
chlordiazepoxide was prevented by coadministration of the
NMDA receptor antagonists CPP, dizocilpine, MK-801, and
ketamine [119–121]. Also, lorazepam-induced tolerance to
its acute anticonvulsant eﬀects was partially prevented with
simultaneous CPP treatment [122]. In contrast, the devel-
opment of tolerance to the anxiolytic eﬀects of diazepam
in a social interaction test was not blocked by concomitant
administration of dizocilpine [123]. This suggests that the
mechanism underlying tolerance to the anxiolytic eﬀects
of diazepam is diﬀerent from that underlying tolerance
to the sedative eﬀects. Increases in cortical mRNA of
NMDA NR1 and NR2B s u b u n i t sh a v eb e e nr e p o r t e di nr a t s
tolerant to diazepam [124, 125], which were prevented by
concomitant treatment with the NMDA receptor antagonist
MK-801 [126]. However, another study showed decreases
in hippocampal NR2B subunits after chronic ﬂurazepam
treatment,eventhoughthetotalamountofNMDAreceptors
was unchanged [127].
In support, after long-term (but not acute) lorazepam
treatment, no diﬀerences were found in the aﬃnity or
density of NMDA receptors, even though increased in
vitro glutamate release and NMDA-induced cGMP eﬄux in
the hippocampus was reported [128]. Together, these data
suggest that NMDA-dependent mechanisms contribute to
the development of benzodiazepine tolerance. However, as
anxiolytic tolerance was not blocked by NMDA receptor
antagonism, the NMDA system could also play a diﬀerential
role in tolerance depending on the speciﬁc behavioral eﬀects
[123]. Moreover, a straightforward glutamate sensitization
may be an oversimpliﬁcation, as tolerance to the sedative
eﬀects of lorazepam after 21-day treatment correlated with
a decreased rather than an increased sensitivity for glutamate
(using
[(3)H] glutamate binding) [129].
Even though the AMPA receptor antagonist GYKI 52466
did not aﬀect the development of tolerance to the sedative
eﬀects of diazepam [121] ,c h a n g e si nA M P Ar e c e p t o r
subunits have been reported to be altered after long-term
benzodiazepine exposure [130]. Speciﬁcally, signiﬁcant
reductions of mGLuR1 (cortex and amygdala) and mGluR2
mRNA (amygdala) were reported in rats treated chronically
with diazepam, even though the eﬀects were complex
and dependent on treatment route (subcutaneous or
intraperitoneal injections). Adding to the complexity of
the published data, another study did not show changes in
hippocampal GluR1-3 subunit proteins following chronic
ﬂurazepam treatment, even though mEPSCs were found and
nonspeciﬁc binding was increased using the AMPA receptor
antagonist
[(3)H] Ro48-8587 [131]. A genetic approach
with GluR1 knockout mice showed that after subchronic
ﬂurazepam treatment, these mice developed a reduced and
incomplete tolerance to the muscle relaxation and sedative
eﬀects of ﬂurazepam, even though acute ﬂurazepam eﬀects
were comparable between knockout and wild-type mice
[132].
With regard to glutamatergic kainate receptors, we found
no pharmacological or genetic studies investigating the
development of tolerance.
Together, the evidence does not support a universal
and replicable glutamatergic component, even though there
are indications that NMDA receptor blockade can prevent
tolerance to at least some behavioral benzodiazepine eﬀects.
However, molecular data are diverse and sometimes incon-
sistent,whicharereminiscentofthemolecularchangesinthe
GABA system after chronic benzodiazepine treatment (see
Section 4.2.2).
4.4. Other Mechanisms
4.4.1. Mechanism 4: Transcriptional and Neurotrophic Factors.
Although the hypothesis that downstream signaling events
adjust in response to chronic exposure to benzodiazepines
seemsplausible,asurprisingpaucityofdataexistinthisﬁeld.
It is tempting to speculate on the expression of diverse helper
GABAA receptor-associated proteins (including GABARAP,
BIG2, PRIP, gephyrin, and radixin) after long-term benzodi-
azepine use (Figure 2). In addition, changes in intracellularly
located cAMP-response-element-binding protein (CREB) or
calcium, vital in various second messenger systems, could be
altered, and prolonged GABA concentrations in a neuronal
culture have been shown to aﬀect voltage-gated calcium
channels [133]. However, until further studies provide
additional proof for chronic benzodiazepine-induced down-
stream intracellular changes, the evidence that this process
plays a role is inconclusive.
Neurotrophic proteins support neuronal survival, synap-
tic growth, and diﬀerentiation throughout the brain via
tyrosine kinase receptors (Trk) and, with lower aﬃnity, via
p75 receptors (p75NTRs) [134]. Neurotrophic factors that
have discovered so far include brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-
4 (NT-4), and nerve growth factor (NGF). Since they act as
potent factors in regulating fast synaptic inhibition, adapta-
tions leading to tolerance following chronic benzodiazepine
treatment could in part be mediated via these neurotrophic
factors. In support, BDNF (and NT-4) was found to acutely
reduce postsynaptic GABAA receptor immunoreactivity via
activation of TrkB receptors [135–139], even though one
study reported an increase [140], and another study reports
that chronic BDNF treatment potentiates GABAergic inhibi-
tion[141].Thisreducedimmunoreactivitywashypothesized
to be caused by a reduction in GABAA receptor surface
expression and was accompanied by reduced postsynaptic
responses with the direct GABAA receptor agonist musci-
mol [142]. Mechanistically, BDNF-induced suppression of
GABAergic signaling was hypothesized to stem from altered
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Figure 3: Functional crosstalk between G-protein coupled receptors (GPCRs) (which are present in the serotonin, dopamine, acetylcholine
system) and GABAA receptors is facilitated through multiple protein kinases and scaﬀold proteins. GABAA receptor β and γ2 subunits
are phosphorylated (P) by PKA and PKC upon the activation of individual GPCRs for dopamine and serotonin. PKA phosphorylation of
GABAA receptor β1a n dβ3 subunits is dependent upon AKAP150/79, which directly interacts with these receptor subunits. AKAP150/79
also binds inactive PKA composed of regulatory (R) and catalytic (C) subunits. In addition, PKC phosphorylates the receptor β1–3 and
γ2 subunits. Upon the activation of the appropriate GPCR, PKC-mediated phosphorylation is facilitated by the direct (but independent)
interaction of the receptor for activated C kinase (RACK-1) and the β isoform of PKC with the GABAA receptor β1–3 subunits. RACK-1
facilitates functional regulation of GABAA receptors by controlling the activity of PKC associated with these proteins. The GABAA receptor
γ2 subunit is also phosphorylated by Src, and this kinase is capable of binding to receptor β and γ2 subunits. Finally, the functional eﬀects of
phosphorylation are diverse and range from inhibitions to enhancements of GABAA receptor activity, dependent upon the receptor subunit
composition. Reprinted by permission from Elsevier, reprinted from [95].
phosphorylation, decreased subunit synthesis, or increased
postsynaptic receptor internalization or diﬀusion [139].
Interestingly, all these proposed mechanisms were already
discussedinthispaper.Thus,neurotrophin-inducedchanges
may not be an independent mechanism, but be a player in a
causal chain of events. Again, to our knowledge, no studies
exist on the eﬀects of chronic benzodiazepine treatment on
neurotrophic expression and functionality.
4.4.2. Mechanism 5: Serotonin, Dopamine, Acetylcholine Sys-
tems. There is ample evidence that the serotonin, dopamine,
and acetylcholine receptor systems can modulate the GABAA
receptor functionality [143–146]( Figure 3). For example,
the receptor for activated C kinase (RACK-1) potentiated
PKC-dependent phosphorylation of GABAA receptors medi-
ated by the activation of muscarinic acetylcholine recep-
tors [145], and serotonergic neurotransmission inhibited
GABAergic signaling via GABAA receptor PKC-dependent
phosphorylation, again with involvement of RACK-1 [144].
Altogether, these neurotransmitter systems act via G-
protein-coupled receptors to activate protein kinases (PKA
and PKC) and scaﬀold proteins that may subsequently
modulateGABAA receptorβandγ2 subunitphosphorylation
(Figure 3)[ 95].
However, studies investigating the role of the sero-
tonin, dopamine, and acetylcholine system in response to12 Advances in Pharmacological Sciences
chronic benzodiazepine treatment are scarce. Three weeks of
diazepam treatment (25mg/day) in healthy male volunteers
resulted in tolerance to the prolactin and growth hormone
response induced by the 5-HT precursor L-tryptophan,
even though sedative eﬀects of L-tryptophan remained
present [147]. Another study showed that chronic diazepam
treatment resulted not only in diazepam tolerance but also
in a very modest reduced eﬃcacy of the 5-HT1A receptor
agonist8-OH-DPATtoinduce ﬂatbody postureandforepaw
treading [148]. In contrast, only acute but not chronic
diazepam treatment decreased basal extracellular dopamine
levels in rats, even though both acute and chronic treatment
regimens could reverse the stress-induced rise of cortical
dopamine levels [149].
4.4.3. Mechanism 6: Neurosteroids. There is ample and
convincing evidence that neurosteroids are endogenous
allosteric regulators that interact with GABAA receptors to
modulate both tonic (extrasynaptic) and phasic (synaptic)
inhibition(forreviews,see[150,151]).Also,acuteorchronic
neurosteroidtreatmentmaychangeGABAA receptorsubunit
expression, especially extrasynaptic α4 and δ subunits [151].
In light of the plasticity-inducing actions of neurosteroids
on inhibitory signaling, long-term enhancement of the
GABA system with benzodiazepines may in turn evoke
changes in the neurosteroids system such as changes in
neurosteroid synthesis and metabolism, although classical
benzodiazepines may diﬀer in their potency to cause such
changes [152]. In support, ovariectomy attenuated the
development of tolerance to the anticonvulsant actions of
diazepam [153]. Moreover, co-administration of the neu-
rosteroids allopregnanolone or pregnenolone (but not dehy-
droepiandrosterone)preventedthedevelopmentoftolerance
after chronic treatment with either triazolam and diazepam
[154]. Adding to the complexity of the putative involvement
of neurosteroids in benzodiazepine tolerance, factors such
as GABAA receptor subunit composition, phosphorylation
mechanisms, and ((extra)synaptic) localization—which are
all factors that were already found to be involved in
tolerance development—inﬂuence the speciﬁc dynamics of
neurosteroid activity.
4.4.4. Conclusion. From our review of the literature on
the various mechanisms that may underlie benzodiazepine
tolerance, it occurs that there is a considerable variance
in the published data. The heterogeneity of the data
lies in the application of diﬀerent methodologies, species,
treatment regimens, and benzodiazepines. Speciﬁcally, we
have considered classical benzodiazepines as a homogenous
drug class since they all lead to a nonspeciﬁc enhancement
of GABAA receptors that contain an α1, α2, α3,o rα5
subunit. However, in vivo pharmacodynamic potency and
pharmacokinetichalf-lifediﬀerencescouldgreatlyimpacton
tolerance processes [7]. In support, subchronic treatment
with diﬀerent classical benzodiazepines lead to diﬀeren-
tial propensity for FG7142-induced seizures in mice, with
triazolam, clonazepam, and diazepam producing around
seizures in around 80% of the mice, whereas alprazolam and
midazolam did so in 60% of the animals and lorazepam
in 40% of the animals [155]. Surprisingly, chlordiazepoxide
did not lead to any precipitated seizures, even though
a comparable GABAA receptor occupancy was obtained.
Therefore, the assumption that classical benzodiazepines act
as a homogeneous class probably complicates the interpreta-
tion of the current literature.
Altogether, it appears that none of the proposed putative
mechanisms can suﬃciently explain tolerance development.
Thus, multiple mechanisms may (synergistically) coexist,
or an additional yet undiscovered mechanism may be
present. However, the complex and adaptive nature of the
GABA system and the existing heterogeneous literature on
benzodiazepine tolerance suggest that one unifying tolerance
mechanism may be a vast oversimplication. In any case,
the proposed tolerance mechanisms are not completely
independent, exempliﬁed by the fact that neurotrophic
factors and neurosteroids are inﬂuenced by GABAA receptor
composition and phosphorylation status, which are them-
selves proposed to be involved in benzodiazepine tolerance.
Unfortunately, the present literature does not consistently
support a clear recommendation in terms of a pharma-
cological GABAA receptor proﬁle (e.g., subunit preference)
to aid in the development of novel and more selective
benzodiazepines that lack tolerance development and are
suitable for long-term treatment.
5.Tolerance toNovelSubtype-Selective
Benzodiazepines
Here, we will review the evidence for tolerance development
with novel GABAA receptor subtype selective compounds
that provide the direct opportunity to evaluate their roles
in tolerance. With the development of subunit-selective
benzodiazepines, it has become possible to dissect the
diﬀerent eﬀects of classical benzodiazepines (see Section 2.2
and Table 2). However, declining eﬃcacy over time is a
complex process which may not be easily attributed to
one speciﬁc α subunit. Still, if novel drugs possess reduced
propensity to lead to tolerance development, this will be
greatly welcomed from a clinical perspective. Continuing
eﬃcacy with these drugs would advance the clinical use of
drugs acting at the GABAA receptor benzodiazepine site.
Unfortunately, not many studies have directly addressed
tolerancedevelopmentusingthesenovelcompounds.Recent
data from our laboratory suggest that no tolerance develops
to the acute hypothermic, anxiolytic, or sedative eﬀect of
diazepam in mice treated for 28 days with the GABAA-α2/α3
selective compound TPA023 (Table 2)[ 156], indicating
that chronic activation of GABAA-α2/α3 receptors does not
lead to anxiolytic tolerance after acute diazepam challenge
(unpublished data). Also, in contrast to morphine, no
analgesic tolerance occurred in rats after a 9-day treatment
with the α2/3 subtype GABAA receptor positive allosteric
modulator L838,417 using a model of neuropathic pain
[157]. From these data, it seems that tolerance development
after chronic administration of GABAA-α2/α3 subtype selec-
tive drugs may not develop, or, alternatively, that tolerance
to diazepam’s sedative actions needs concomitant activation
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hypothesis, ligands that do not bind to the α5 subunit such
as zolpidem have a reduced tendency to engender tolerance
[158, 159], supported by studies in which chronic treatment
with zolpidem (but not midazolam) did not produce any
tolerance to sedative and anticonvulsant eﬀects in mice and
rats [160–162].
In addition to studies directly assessing tolerance, several
studies have investigated the precipitated withdrawal after
(sub) chronic treatment with subtype-selective compounds.
Compounds with selective eﬃcacy at α2, α3,a n dα5 GABAA
receptor subtypes were shown to lead to diﬀerential seizures
susceptibility in mice in response to the inverse agonist FG-
7142 [155]. Chronic treatment with zolpidem, as well as
the selective compounds L-838,417 (partial agonist at α2
GABAA, α3GABAA,a n dα5GABAA receptors) and SL651498
(full agonist at α2GABAA and α3GABAA receptors, partial
agonist at α1GABAA and α5GABAA receptors), did not
resultinseizuresfollowingFG-7142administration[31,155]
(Table 2). Similarly, chronic treatment with TPA023 (partial
agonist at α2GABAA, α3GABAA,a n dα5GABAA receptors)
also did not result in FG-7142-induced seizures in mice
[156]. However, because these studies do not speciﬁcally
addresstolerancedevelopment,therathergeneralconclusion
from these studies is that partial or selective modulation
of the GABAA receptor results in a reduced liability for
physical dependence. Thus, it is important to note that, even
though zolpidem does not seem to engender any obvious
tolerance development, zolpidem can lead to withdrawal
symptoms that are comparable to those seen after chronic
classical benzodiazepine treatment [29, 77]. Thus, tolerance
andwithdrawalsymptomsmayconstituteseparateentitiesin
benzodiazepine dependence. In support, one study demon-
strated that marked withdrawal symptoms appeared upon
abrupt discontinuation of chronic clorazepate treatment in
dogs, even though tolerance was present to a rather limited
extent [163].
Together, it can be concluded that so far, α2/α3 sub-
type selective compounds have neither been found to
lead to tolerance nor withdrawal symptoms. This would
constitute a signiﬁcant improvement over currently used
benzodiazepines, even though the anxiolytic proﬁle of these
compounds remains to be determined [164], and abuse
liability may still be present [8]. However, interpretations
should be made with caution since chronic treatment with
nonselective partial positive allosteric modulators such as
bretazenil did neither result in anticonvulsant tolerance [54,
59, 60] nor in FG-7142-precipitated seizures [155]. These
studies implicate that the potency of classical and subtype-
selective compounds, in addition to or despite subtype
selectivity, may also be of importance in the development
of tolerance. It could be also hypothesized that low eﬃcacy
at the α1 subunit, rather than selectivity or reduced eﬃcacy
at α2/α3 subtypes, may be the causal mechanism preventing
tolerance development. Also, the clinical anxiolytic eﬃcacy
of α2/α3 subtype selective compounds has not yet been
established.Inadditiontoaspeciﬁceﬃcacyproﬁle,tolerance
development may also depend on a compound’s aﬃnity
at certain GABAA receptor subtypes. This way, tolerance
processes may be diﬀerent with aﬃnity-selective compounds
such as zolpidem compared to eﬃcacy-selective compounds
such as TPA023. Circumstantial evidence stems from the
fact that α1-preferential aﬃnity-selective compounds such as
zolpidem produce physical dependence [165], even though
the compound TPA123 that possesses 23% eﬃcacy at the
α1 subunit (but is not aﬃnity selective) did also result in
physical dependence [8]. However, based on the currently
available evidence, no deﬁnite conclusions can be drawn
regarding the subtype involved in tolerance. Also, it is
not possible to distinguish tolerance processes in selective
binding (aﬃnity) and selective activation (eﬃcacy).
6. Conclusion
In the present paper, we summarized the rather inconsistent
data regarding changes in several neurotransmitter systems
to explain the development of tolerance. Speciﬁcally, we
addressed possible changes at the level of (i) the GABAA
receptor (subunit expression and receptor coupling), (ii)
intracellular changes stemming from transcriptional and
neurotrophic factors, (iii) ionotropic glutamate receptors,
(iv) other neurotransmitters (serotonin, dopamine, and
acetylcholine systems), and (v) the neurosteroid system.
From the large variance in the studies, it appears that
either diﬀerent (simultaneous) tolerance mechanisms occur
depending on the benzodiazepine eﬀect, or that one
tolerance-inducing mechanism depends on the activated
GABAA receptor subtypes. This is not unlikely, given that
tolerance is a heterogeneous process that occurs at diﬀerent
rates for the various eﬀects and also depends on the proﬁle
of the (subtype selective) benzodiazepine. Adaptations could
then occur on diﬀerent time scales depending on the
receptor subtype and brain region involved. In line with
this hypothesis, tolerance develops relatively quickly for
the sedative and anticonvulsant actions of benzodiazepines,
whereas tolerance to anxiolytic and amnesic eﬀects most
probably do not develop at all. It is intriguing that anxiolytic
eﬀects of classical benzodiazepines may not decline during
prolonged treatment. In addition to subtype selectivity,
additional factors may be important for a (subtype-selective)
benzodiazepine to cause tolerance, including GABAA recep-
tor potency (eﬃcacy) and in vivo receptor occupancy over
time. The ﬁnding that partial agonists with an overall but
comparable lower eﬃcacy at all α subunits of the GABAA
receptor such as bretazenil did not result in anticonvulsant
tolerance raises the possibility that chronic clinical use of
these compounds is associated with a lower tolerance.
An important question is how the development of toler-
ance of benzodiazepines could be reduced. One interesting
suggestion could be—rather than intermittent use that can
be deﬁned by an individual—to develop benzodiazepine
dosingscheduleswithvaryingdailydosesincludingplacebos.
This could result in continued clinical eﬃcacy (obviously
depending on the indication) and utilize the placebo eﬀect.
The other possibility to reduce tolerance is the currently
developing and promising body of literature on subtype-
selective GABAA receptor PAMs. From the literature we
reviewed, it appears that α2/α3 subtype selective compounds
do not lead to tolerance or withdrawal symptoms. However,14 Advances in Pharmacological Sciences
theunderlyingmechanism(reducedα1 eﬃcacyoragenerally
reduced eﬃcacy proﬁle) is unknown. Also, it is presently
unclear whether this lack of tolerance also applies to α1-
and α5-selective GABAergic positive allosteric modulators,
although a broad and unspeciﬁc tolerance resulting from
selective(andoftenlowpotency)compoundsseemsunlikely.
In conclusion, the development of tolerance following
chronic benzodiazepine treatment is a complex process in
which multiple processes may simultaneously act to cause
varying rates of tolerance depending on the studied eﬀect
and the administered drug. There is no convincing evidence
that subtype-selective compounds acting at the benzodi-
azepinesiteleadtotoleranceatalevelcomparabletoclassical
benzodiazepines. If this is indeed the case, one consequence
may be that such subtype-selective compounds are unlikely
to engender clinical tolerance, which would be a clinically
signiﬁcant improvement over classical benzodiazepines.
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